pembrolizumab,lenvatinib,Cabozantinib,Sorafenib,Atezolizumab
eisai,merck,roche,Exelixis,bayer
['lba3', 'hcc', 'lba34', 'leap-002', 'pembro', 'lenva']
 leap-002 phase-iii presented at lba34 lenvatinib &amp; pembrolizumab in 1st line #hcc len/pem: orr 26%, mpfs 8.2 mo, mos 21mo-&gt; not enough lenva stunning: orr 17%, mpfs 8.1 mo, mos 19 mo 2nd after cosmic-&gt; moa, statistics...? #livertwitter 
Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine